Abciximab is a platelet aggregation inhibitor that blocks platelets from sticking together and forming blood clots. It is the Fab fragment of the chimeric human-murine monoclonal antibody 7E3. The drug binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets. Thus, inhibiting aggregation, that is, clotting.
It is a prescription drug.
Abciximab is used to reduce the chances of heart attack in patients who are required to undergo percutaneous coronary intervention (PCI). This is a procedure where the blocked arteries of the heart are opened. During the procedure to open the blocked arteries, formation of blood clots can occur. These blood clots can block a blood vessel in the heart, leading to a heart attack. Abciximab can help reduce the occurrence of these blood clots by prevention of clumping of the platelets. Other drugs used along with abciximab to prevent the clotting of blood include aspirin and heparin.
Abciximab is given in the form of an injection at a hospital or doctor’s clinic.
The common side effects of abciximab include:
Abciximab is NOT recommended for use in children.
Studies have found no difference in the safety or efficacy of the drug in patients aged 65 to less than 75 as compared to younger patients.
Abciximab comes under Pregnancy Category C. There is no information whether Abciximab can cause fetal harm when given to pregnant women. Thus, it should be given in pregnancy only when the potential benefits outweigh potential risks.
There is no proof if abciximab is excreted in human milk. Thus, one should exercise caution when giving the drug to a nursing woman.
There are drugs that can interact with abciximab. Inform your doctor if you are on anticoagulants (warfarin and heparin), dipyridamole, NSAIDs (ibuprofen), ticlopidine, or thrombolytics.
The drug may interact with other medications as well. Thus, discuss all the medications and supplements you are currently using with your doctor.
Each dose varies from patient to patient. Thus, follow the dose advised by the doctor. For the injectable form adults are given 250 micrograms (MCG) per kg of body weight injected 10 to 60 minutes before the procedure. The maintenance dose is given at 0.125 mcg/kg of body weight per minute (maximum of 10 mcg/minute) by IV for 12 hours.
Patients with unstable angina will require 250 mcg/kg of body weight injected. The maintenance dose is given at10 mcg/minute by IV for 18 to 24 hours, that ends 1 hour after the procedure is complete.
Only a healthcare provider can handle and store abciximab. Keep the drug away from the reach of children and pets.
Written by: healthplus24.com team
Date last updated: June 08, 2015
Subscribe to our email newsletter.